Research and Markets: Revenues from Sales of Omic Technology-based Products which in 2004 Totaled Nearly $1.5 billion are Projected to Increase to $2.3 billion by 2009

Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c22460) has announced the addition of Drug Targets from Genomics: Evolving Tools for Discovery to their offering

"Drug Targets from Genomics: Evolving Tools for Discovery" seeks to examine the roles omic technologies play in pharma R&D, to asses their value to pharma, and to predict their future role and value. This report analyzes current and projected revenues from sales of omic technology-based products (reagents and consumables), which in 2004 totaled nearly $1.5 billion. Revenues are projected to increase to $2.3 billion by 2009. Also provided is a breakdown of revenues into transcriptomic, proteomic, metabolomic, and genotyping categories.

Viewed from the perspective of the life sciences, the last century ended with a bang. Researchers sequenced the human genome, massively parallel analyses became possible starting with the introduction of DNA microarrays, SNP-based genotyping studies promised to reveal new disease genes and possibly new drug targets, and pharmacogenomics promised to herald a new era of personalized medicine. Abundant venture capital funding and a wide open IPO window fueled exciting developments in commercialization of omic technologies.

Big pharma invested heavily in gene discovery companies in hopes of finding valuable new targets, and in omic tool companies, which promised improved R&D productivity via new and better targets, prediction of compound toxicity, early attrition of unsuitable compounds, and more responsive clinical study populations. Promises of fast and dramatic benefits soon gave way to a more sobering reality. Omic-based results, while intriguing, needed large inputs of follow-on biological experimentation in order to see if their perceived potential could be realized. The process continues today. Some strides have been made, but the jury is still out on the big picture.

This report seeks to examine the roles omic technologies play in pharma R&D, to assess their value to pharma, and to predict their future role and value. Following introductory and review material in Chapter 1 and 2, Chapter 3 starts with a historical perspective on pharma R&D and the development and introduction of omic technologies therein. It continues with detailed descriptions of the technologies themselves and how they have come to be applied in pharma. Chapter 4 examines the role of omic technologies in pharma today by providing answers to a series of provocative questions. Chapter 5 examines the market implications of these technologies from the perspective of tool providers, and Chapter 6 profiles individual companies from the perspective of omic technologies, and the report concludes with Chapter 7, which contains transcripts of interviews with six industry experts.

Companies mentioned:

- Abbott Laboratories
- AstraZeneca PLC
- Bristol-Myers Squibb
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline
- Merck & Co., Inc.
- Millennium Pharmaceuticals
- Novartis International AG
- Pfizer, Inc.

For more information visit http://www.researchandmarkets.com/reports/c22460

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980